These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7589074)

  • 1. CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide.
    Grohmann U; Bianchi R; Fioretti MC; Fallarino F; Binaglia L; Uyttenhove C; Van Pel A; Boon T; Puccetti P
    Eur J Immunol; 1995 Oct; 25(10):2797-802. PubMed ID: 7589074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
    Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
    J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a skin test assay to determine tumor-specific CD8+ T cell reactivity.
    Puccetti P; Bianchi R; Fioretti MC; Ayroldi E; Uyttenhove C; Van Pel A; Boon T; Grohmann U
    Eur J Immunol; 1994 Jun; 24(6):1446-52. PubMed ID: 8206103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells.
    Grohmann U; Silla S; Belladonna ML; Bianchi R; Orabona C; Puccetti P; Fioretti MC
    Cell Immunol; 1997 Nov; 181(2):109-19. PubMed ID: 9398398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state.
    Grohmann U; Bianchi R; Ayroldi E; Belladonna ML; Surace D; Fioretti MC; Puccetti P
    J Immunol; 1997 Apr; 158(8):3593-602. PubMed ID: 9103420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cells, interleukin 12, and CD4+ lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide.
    Grohmann U; Fioretti MC; Bianchi R; Belladonna ML; Ayroldi E; Surace D; Silla S; Puccetti P
    Crit Rev Immunol; 1998; 18(1-2):87-98. PubMed ID: 9419451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells.
    Streilein JW; Niederkorn JY
    J Immunol; 1985 Mar; 134(3):1381-7. PubMed ID: 3155766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.
    Bour H; Horvath C; Lurquin C; Cerottini JC; MacDonald HR
    J Immunol; 1998 Jun; 160(11):5522-9. PubMed ID: 9605156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct subsets of accessory cells activate Thy-1+ triple negative (CD3-, CD4-, CD8-) cells and Th-1 delayed-type hypersensitivity effector T cells.
    Matsushima GK; Stohlman SA
    J Immunol; 1991 May; 146(10):3322-31. PubMed ID: 1673982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
    Frey AB; Cestari S
    Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides.
    Franke ED; Corradin G; Hoffman SL
    J Immunol; 1997 Oct; 159(7):3424-33. PubMed ID: 9317141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of anti-T cell monoclonal antibodies to prevent acute tumor allograft rejection is associated with their inability to deplete or inactivate T cells at the site of rejection.
    Rakhmilevich AL
    Transplantation; 1994 Jul; 58(1):72-80. PubMed ID: 7913562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
    Tomita Y; Mayumi H; Eto M; Nomoto K
    J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes.
    Wang R; Charoenvit Y; Corradin G; De La Vega P; Franke ED; Hoffman SL
    J Immunol; 1996 Nov; 157(9):4061-7. PubMed ID: 8892640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17kDa.
    Dobaño C; Doolan DL
    Mol Immunol; 2007 Apr; 44(11):3037-48. PubMed ID: 17303242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
    J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex.
    Grohmann U; Belladonna ML; Bianchi R; Orabona C; Silla S; Squillacioti G; Fioretti MC; Puccetti P
    Cancer Immunol Immunother; 1999 Jul; 48(4):195-203. PubMed ID: 10431689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.